IO102-IO103 in combination with pembrolizumab
IOB-022
Phase 2 small_molecule completed
Quick answer
IO102-IO103 in combination with pembrolizumab for Lung Cancer Non Small Cell is a Phase 2 program (small_molecule) at IO Biotech with 1 ClinicalTrials.gov record(s).
Program details
- Company
- IO Biotech
- Indication
- Lung Cancer Non Small Cell
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed